WellSpring

Wellspring Biosciences is a private biopharmaceutical company based in San Diego, California, that specializes in the discovery and development of small molecule therapeutics for oncology. The company is widely recognized for its groundbreaking research in targeting the KRAS G12C mutation, having developed the first generation of covalent inhibitors that paved the way for a new class of cancer treatments. Wellspring operates through a strategic collaboration with Janssen Biotech and works in tandem with its sister company, Araxes Pharma, to advance a pipeline of precision medicines targeting the RAS signaling pathway. Their platform utilizes advanced structural biology and medicinal chemistry to address high-value, historically undruggable targets in solid tumors. The company's lead programs focus on inhibiting key nodes in the MAPK signaling pathway to treat genetically defined cancers.